Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Radiotherapy with SOX, Apatinib, and Camrelizumab for Gastric/GEJ Cancer
NCT07026149Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoint: Pathological Complete Response. Started Jun 2025; status: recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07026149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026149.